9/13/2011 10:37:42 AM
BOTHELL, Wash. & OXFORD, England--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Oxford BioTherapeutics (OBT) today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer. Under the collaboration, OBT will generate panels of monoclonal antibodies against novel tumor-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP®) database. The antibodies generated by OBT will then be screened for activity using Seattle Genetics’ ADC technology. The resulting ADCs may be selected by each company for further development and commercialization.
comments powered by